Login to Your Account



Financings NEWS

DUBLIN – A mere four months after its formation, German startup Iomx Therapeutics GmbH raised €40 million (US$44.6 million) in a series A round to develop antibody-based therapeutics against tumor-derived immune checkpoint targets.

DUBLIN – Eyevensys SAS extended its series A funding round with an injection of €1.5 million (US$ 1.7 million) from Pontifax Venture Capital, taking the total raise to €9 million. The Paris-based company is pioneering gene delivery to the eye using electroporation or, in its own parlance, “electro-transfection.”

As Bluebird Bio Inc. soaked up most of the spotlight on gene therapy by opening the global phase III trial of its Lentiglobin BB305 candidate in patients with beta-thalassemia, stealthy Avexis Inc. sought to extend its cash runway.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: